Sapu Nano, the 45‑percent owned joint venture of Oncotelic Therapeutics, disclosed on December 3, 2025 that its intravenous Deciparticle™ formulation of everolimus, Sapu003, achieved a 67‑fold reduction in gastrointestinal drug accumulation compared with the oral drug. The data were presented at the 2025 San Antonio Breast Cancer Symposium, which ran from December 9‑12, 2025.
The study showed that Sapu003 produced only 36–48 × plasma levels in stomach, small intestine, and large intestine tissues, whereas oral everolimus reached 2,448 ×, 750 ×, and 323 ×, respectively. This dramatic decrease in GI exposure is expected to translate into improved tolerability while preserving systemic exposure and the drug’s metabolic profile.
Sapu Nano’s Deciparticle platform encapsulates hydrophobic molecules into sub‑20 nm particles, enabling consistent weekly IV dosing and scalable clinical‑trial supply from its ISO‑5 cGMP facility. The platform’s versatility positions the company to extend the technology to other oncology and immunology candidates beyond everolimus.
The data support Sapu Nano’s strategy to deliver a more tolerable, injectable version of everolimus, potentially expanding its use in indications where oral therapy is limited by GI toxicity. The milestone also strengthens the joint venture’s competitive advantage and sets the stage for future clinical development in oncology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.